Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golcadomide + PRD in Relapsed/Refractory CNS Lymphoma
NCT07608731Phase 1Not yet recruiting
- Sponsor
- Allison Winter
- Start
- Oct 2026
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of golcadomide in central nervous system lymphoma, sponsored by Allison Winter. Primary endpoints: Safety of Golcadomide + Pemetrexed, Rituximab and Dexamethasone up to 6 months and Maximum Tolerated Dose up to 6 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
golcadomide
03
Conditions
central nervous system lymphoma
Beyond the preview
Go deeper on NCT07608731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07608731.